





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO. FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/937,221 07/18/2002	Kunihiko IIzuka	2001-1460A	6705
513 7590 06/09	03		
WENDEROTH, LIND & PONACK, L.L.P.		EXAMINER	
2033 K STREET N. W. SUITE 800	1	DENTZ, BERNARD I	
WASHINGTON, DC 20006-10	I	ART UNIT	PAPER NUMBER
		1625	. 7
		DATE MAILED: 06/09/2003	·

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n No.	Applicant(s)		
•	09/937,221	IIZUKA ET AL.		
Office Action Summary	Examiner	Art Unit		
	Bernard Dentz	1625		
The MAILING DATE of this communication app	ears on the cover sheet with the	correspondence address		
Period for Reply	(10 OFT TO EVENE (1401)T	VO) 50011		
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be within the statutory minimum of thirty (30) d fill apply and will expire SIX (6) MONTHS fro cause the application to become ABANDON	timely filed ays will be considered timely. im the mailing date of this communication. IED (35 U.S.C. § 133).		
Status		•		
1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) ☐ This	· is action is non-final.			
<u>, </u>		prospection as to the merits is		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims		•		
4) Claim(s) 1-21 is/are pending in the application				
4a) Of the above claim(s) is/are withdrav	vn from consideration.			
5) Claim(s) is/are allowed.		•		
6) Claim(s) is/are rejected.	•	·		
7) Claim(s) is/are objected to.				
8) Claim(s) 1-21 are subject to restriction and/or example at the subject to restrict and subject to restric	election requirement.			
Application Papers OND The specification is objected to by the Evamine	•			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accept		zaminer		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.				
12) The oath or declaration is objected to by the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120	•			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:				
1. ☐ Certified copies of the priority documents	s have been received.			
2. Certified copies of the priority documents		ation No		
3. Copies of the certified copies of the prior application from the International Bu	reau (PCT Rule 17.2(a)).			
* See the attached detailed Office action for a list 14) Acknowledgment is made of a claim for domesti	• •	•		
 a) The translation of the foreign language pro 15) Acknowledgment is made of a claim for domesting the companion of the foreign language pro 	· -			
Attachment(s)	,,	·		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informa	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)		
S. Patent and Trademark Office				

Art Unit: 1625

Claims 1, 6, 11 and 16 are improper unsupported claims which control if issue as a patent.

Thus these claims are considered drawn to a separate invention, albeit improper.

and Rc. Thus the 3 values of Ra

The generic claim is huge in the definition of Ra are 1 of the indicators for separate inventions. Rc is considered to have 4. The first 2 are monocyclic containing

1 N and monocyclic containing more than 1 N respectively. The third and fourth are

Thus restriction is required as follows:

I. Claims 1, 6, 11 and 16 drawn to use of any compound which affects the Rho receptor to treat interstitial pneumonia or pulmonary fibrosis.

polycyclic containing 1N and polycyclic containing more than 1N respectively.

- II. Claims 2-5, 7-10, 12-15 and 17-21 drawn to compounds and associated subject matter wherein R_a contains a 1, 4-substituted cyclohexane group and R_c is 1N monocyclic.
- III. Claims 2-4, 7-9, 12-14 and 17-19 and 21 drawn to compounds and associated subject matter wherein R_a contains an at least disubstituted benzene ring where the relative positions of the 2 main substituents not fixed as in the above cyclohexano containing group and R_c is 1N monocyclic.
- IV. Claims 2, 7, 12, 17 and 21 drawn to compounds and associated subject matter wherein R_a contains a preparation or 3, 4-dehydropiperidine group and R_c is 1N monocyclic.

Application/Control Number: 09/937,221

Art Unit: 1625

- V. Claims 2, 3, 7, 8, 12, 13, 17, 18 and 21 where R_a is value a and R_c is 1N polycyclic.
- VI. Claims 2, 3, 7, 8, 12, 13, 17, 18 and 21 wherein R_b is value b and R_c is 1N polycyclic.
- VII. Claims 2, 7, 12, 17 and 21 wherein Rb is value C and Rc is 1N polycyclic.
- VIII. Claims 2, 3, 7, 8, 12, 13, 17, 18 and 21 where R_a is value a and R_c is poly N monocyclic.
- IX. Claims 2, 3, 7, 8, 12, 13, 17, 18 and 21 wherein R_a is value b and R_c is poly N monocyclic.
- X. Claims 2, 7, 12, 17 and 21 where Rb is value C and R_c is poly N monocyclic.
- XI. Claims 2-4, 7-9. 12-14, 17-19 and 21 where Rb is value a and $R_{\rm c}$ is poly N polycyclic.
- XII. Claims 2, 3, 7, 8, 12, 13, 17, 18 and 21 where Rb is value b and Rc is poly N polycyclic.
- XIII. Claims 2, 7, 12, 17 and 21 where Rb is value C and R_c is poly N polycyclic.

Although the classification have not been specifically set out it can be appreciated from the list of values for "Optionally substituted heterocyclic containing nitrogen" for R_c set out on pages 22 and 23 that there are many all over classes 544, 546 and 548.

Thus restriction for effective examination purposes is proper in view of the directly above and earlier comments on the diversity and breadth of the subject matter.

Application/Control Number: 09/937,221

Art Unit: 1625

In case no generic claims are later found allowable applicants must now elect a single disclosed species.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is (703) 308-4544. The examiner can normally be reached on Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alan Rotman can be reached on (703) 308-4698. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 3084556 for regular communications and (703) 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Dentz/LR June 5, 2003

EERNARD DENTZ PRIMARY EXAMINER GROUP 1470

Page 4